Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet

dc.contributor.author Gugu, M.
dc.contributor.author Acharya, S.
dc.contributor.author Pira, D.
dc.contributor.author Poletti, S.
dc.contributor.author di Flora, A.
dc.contributor.author Saksida, T.
dc.contributor.author Figueira, I.
dc.date.accessioned 2025-02-25T19:32:13Z
dc.date.available 2025-02-25T19:32:13Z
dc.date.issued 2025
dc.description.abstract Parkinson’s disease (PD) affects more than one million people in the EU. It currently has no definitive cure, meaning that patients rely only on symptomatic treatments, which themselves are burdened by side effects. The need for advancements in both knowledge and available treatments is thus strongly felt by patients, caregivers, and health operators. This unmet need sparked the idea of orchestrating a collaborative effort via a common network – IMMUPARKNET (The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork). The IMMUPARKNET COST Action focuses on challenges in PD and its related crosstalk with immune response. Although widely recognized, the role of immunity in the onset and development of PD is still unclear. The main goal of IMMUPARKNET is to fill this knowledge gap by establishing an innovative, interdisciplinary research network and fostering exchanges of expertise among specialists from different countries and institutions. As we gather scientists and clinicians who study immunity in PD and related fields, IMMUPARKNET will establish the first nucleus of a multidisciplinary ecosystem that aims to harmonize efforts and approaches, both in research and clinical practice, to boost the development of ground-breaking treatments for PD. Through meetings, training schools, webinars, position papers, and review manuscripts, IMMUPARKNET will lead fruitful exchanges of know-how among experts in the field. The IMMUPARKNET structure revolves around 5 working groups, with a total of 157 active members from 34 different countries. Of these active members, 58.5% are young researchers, while 67.5% come from Inclusiveness Target Countries (ITC - less research-intensive COST Members; https://www.cost.eu/about/members/). IMMUPARKNET output will facilitate the improved sharing and development of research resources, straightening the road to novel treatments and identifying where existing ones can be repurposed, all, ultimately and hopefully, finding a cure for PD. Copyright: © 2025 Gugu M et al. en_US
dc.identifier.doi 10.12688/openreseurope.17547.2
dc.identifier.issn 2732-5121
dc.identifier.scopus 2-s2.0-85217444470
dc.identifier.uri https://doi.org/10.12688/openreseurope.17547.2
dc.identifier.uri https://hdl.handle.net/20.500.14365/5950
dc.language.iso en en_US
dc.publisher F1000 Research Ltd en_US
dc.relation.ispartof Open Research Europe en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Immune Response en_US
dc.subject Network en_US
dc.subject Parkinson'S Disease en_US
dc.title Immunity Unveiled: a Translational Network for Tackling Parkinson's Disease – Immuparknet en_US
dc.type Letter en_US
dspace.entity.type Publication
gdc.author.scopusid 57425554200
gdc.author.scopusid 57224739314
gdc.author.scopusid 58421235000
gdc.author.scopusid 59550938400
gdc.author.scopusid 58661476000
gdc.author.scopusid 46061288700
gdc.author.scopusid 6701468226
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C5
gdc.coar.access metadata only access
gdc.coar.type text::letter
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp Gugu M., Preclinical Department, Faculty of Technical Medical Sciences, University of Elbasan “Aleksandër Xhuvani”, Elbasan, Albania; Acharya S., Luxembourg and Faculty of Science, Technology and Medicine, University of Luxembourg, Luxembourg, Luxembourg, Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Luxembourg, Luxembourg; Pira D., Faculty of Medicine, Izmir University of Economics, Izmir, Türkiye; Poletti S., Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; di Flora A., Center for Research in Medical Pharmacology, School of Medicine, University of Insubria, Lombardy, Varese, Italy; Saksida T., Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia; Pilipenko V., Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga, Riga, Latvia; Romero-Ramos M., Danish Research Institute of Translational Neuroscience – DANDRITE, Department of Biomedicine, Aarhus University, Central Denmark Region, Aarhus, Denmark; Marino F., Center for Research in Medical Pharmacology, School of Medicine, University of Insubria, Lombardy, Varese, Italy; Muñoz Delgado L., Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC, Universidad de Sevilla, Andalusia, Seville, Spain; Nikolovski N., Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia; Gursoy Ozdemir Y., Department of Neurology, School of Medicine, Koç University, İstanbul, Istanbul, Türkiye; Lawson D., University of Eastern Piedmont, Novara, Italy; Comi C., Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, S. Andrea Hospital, Vercelli, Italy; Figueira I., NOVA Medica School, Faculdade de Ciências Médicas (NMS|FCM), Universidade Nova de Lisboa, Lisbon, Lisbon, Portugal en_US
gdc.description.publicationcategory Diğer en_US
gdc.description.scopusquality Q2
gdc.description.volume 4 en_US
gdc.description.wosquality N/A
gdc.identifier.openalex W4406756540
gdc.index.type Scopus
gdc.oaire.accesstype HYBRID
gdc.oaire.diamondjournal false
gdc.oaire.impulse 1.0
gdc.oaire.influence 2.4986813E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Parkinson's disease
gdc.oaire.keywords network
gdc.oaire.keywords Parkinson's disease;immune response;network
gdc.oaire.keywords 610
gdc.oaire.keywords Open Letter
gdc.oaire.keywords immune response
gdc.oaire.keywords General
gdc.oaire.keywords Parkinson's disease; immune response; network
gdc.oaire.popularity 3.110569E-9
gdc.oaire.publicfunded false
gdc.openalex.collaboration International
gdc.openalex.fwci 1.5123
gdc.openalex.normalizedpercentile 0.77
gdc.openalex.toppercent TOP 10%
gdc.opencitations.count 0
gdc.plumx.newscount 1
gdc.plumx.scopuscites 1
gdc.scopus.citedcount 1
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery e9e77e3e-bc94-40a7-9b24-b807b2cd0319

Files